United Kingdom· GB-APID-39929311000001104
Pemazyre 13.5mg tablets
A pemigatinib product containing pemigatinib, registered in United Kingdom by Incyte Biosciences UK Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Pemigatinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EN02 (pemigatinib), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Pemigatinib · ATC L01EN02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pemigatinib costs, country by country.
Normalised to the WHO defined daily dose (9 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pemigatinib · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1227.26
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Pemigatinib
- Manufacturer
- Incyte Biosciences UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01EN02
- ATC class
- Pemigatinib
- Defined daily dose
- 9 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin07640159430766
- gtin7640159430766
- gtin7640159434405
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
71 interactions on record for pemigatinib.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pemigatinib · interactions on record
71 records
- 30 severe
- 41 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pemigatinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPEMAZYREIncyte Biosciences Distribution B.V., Amsterdam
- SwitzerlandPemazyre 13,5 mg, comprimésIncyte Biosciences International Sàrl
- United StatesPEMAZYREIncyte Corporation
- FrancePEMAZYRE 13,5 mg, compriméINCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- CanadaPEMAZYREINCYTE CORPORATION
- IcelandPemazyreIncyte Biosciences Distribution B.V.
- NetherlandsPemazyre 13,5 mg, tablettenIncyte Biosciences Distribution B.V.
- NorwayPemazyreIncyte Biosciences Distribution B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pemazyre
- Liechtenstein · Pemazyre
- Norway · Pemazyre
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eb3e326d-1f04-446b-be73-c06ddd82e8f8 GET /v1/drugs/eb3e326d-1f04-446b-be73-c06ddd82e8f8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "39929311000001104",
"desc": "Pemazyre 13.5mg tablets (Incyte Biosciences UK Ltd)",
"form": "Oral tablet",
"vpid": "39934311000001103",
"source": "dmd",
"vtm_id": "871708007",
"strength": "13.5 mg",
"substance": "Pemigatinib",
"ingredient": "Pemigatinib",
"supplier_code": "22704211000001101"
}See everything about pemigatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.